Axovant Sciences Ltd.

121 articles about Axovant Sciences Ltd.

• 

  A Whole New Era Begins as Roivant and Montes Archimedes Merge in Cash-Rich SPAC

  5/3/2021

  Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC). Once the deal is closed, outstanding shares and warrants of MAAC will be traded for newly issued shares and warrants of the company.
• 

  BioSpace Movers & Shakers, Oct. 16

  10/16/2020

  Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.

• Axovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 2020

  8/11/2020

  Data readouts for AXO-Lenti-PD and AXO-AAV-GM1 remain on-track for Q4 2020 Completed 3-year manufacturing and supply agreement with Oxford BioMedica for AXO-Lenti-PD Company had $55.5 million of cash and cash equivalents as of June 30, 2020

• Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica for Manufacturing and Supply of AXO-Lenti-PD

  7/31/2020

  Axovant Gene Therapies Ltd, a clinical-stage company developing innovative gene therapies for neurological diseases, announced that its subsidiary has signed a three-year Clinical Supply Agreement with Oxford Biomedica plc, a leading gene and cell therapy group.

• Axovant Announces Year-End Financial Results and Expected Key Clinical Milestones in Q4 2020

  6/10/2020

  Completed enrollment of cohort 2 of SUNRISE-PD Phase 2 study of AXO-Lenti-PD in Parkinson’s disease, with data from this cohort expected in Q4 2020

• Axovant Completes Enrollment of Low-Dose Cohort in Phase 1/2 Study of AXO-AAV-GM1 and Expands Study to Include Type I (Infantile Onset) Patients with GM1 Gangliosidosis

  6/8/2020

  Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it has completed enrollment in the low-dose cohort of the Phase 1/2 (“Stage 1”) study for Type II

• Axovant Gene Therapies to Present at the 2020 Jefferies Global Virtual Healthcare Conference

  5/28/2020

  Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that Parag Meswani, Pharm.D., SVP of Commercial Strategy and Operations, will present at the Jefferies Global Virtual Healthcare Conference. Presentation Details: Date:   Thursday, June 4, 2020 Time:   3:00 PM EDT Webcast link:   http://wsw.com/webcast/jeff

• Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy

  5/7/2020

  Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced upcoming presentations regarding its investigational gene therapy programs, AXO-Lenti-PD and AXO-AAV-GM2 at the 23 rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), held virtually on May 12 th to May 15 th , 2020. Oral Presentation Details: Oral P

• Axovant Announces Full Prepayment of Outstanding Loan from Hercules CapitalCompany’s balance sheet is now free of debt

  4/24/2020

  Axovant Gene Therapies Ltd. a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it had prepaid in full its $15.7 million outstanding loan from Hercules Capital, Inc. together with interest, fees and other amounts due. Following the prepayment, the credit facility and loan agreement with Hercules Capital, Inc. was terminated, and all obligations, liens and security inter

• Axovant Announces Partnership with Invitae to Increase Access to Genetic Testing and Accelerate Diagnoses of GM1 and GM2 Gangliosidosis

  4/15/2020

  Partnership to reduce barriers to genetic diagnosis through sponsored testing for lysosomal storage diseases Initiative supports identification of patients with GM1 and GM2 gangliosidosis who are currently misdiagnosed or undiagnosed NEW YORK and BASEL, Switzerland, April 15, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, today announced its collaboration with Invitae, a leading medical gene

• Axovant Provides Business and Operations Update During the COVID-19 Pandemic

  4/8/2020

  Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, provides a business and operations update during the COVID-19 pandemic.

• Axovant to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

  3/31/2020

  Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, announced that management will participate in the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day on Friday, April 3, 2020.

• Axovant Gene Therapies Announces Closing of $74.7 Million Public Offering of Common Shares and Prefunded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

  2/24/2020

  Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the closing of its previously announced underwritten public offering of 16,631,336 common shares, including the full exercise of the underwriters’ option to purchase 2,600,000 additional common shares, at a price to the public of $3.75 per share.

• Axovant Gene Therapies Announces Pricing of $65 Million Public Offering

  2/20/2020

  Axovant Gene Therapies Ltd. announced the pricing of its underwritten public offering of 14,031,336 of its common shares at a price to the public of $3.75 per share.

• Axovant Gene Therapies Announces Commencement of Public Offering

  2/19/2020

  Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares and pre-funded warrants to purchase its common shares.

• Axovant Announces Financial Results for Third Fiscal Quarter and Nine Months Ended December 31, 2019

  2/10/2020

  Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies, provided financial results for its third fiscal quarter ended December 31, 2019.

• Axovant Announces Positive 12-month Data on AXO-Lenti-PD and Provides Updates Across Gene Therapy Pipeline Programs

  1/13/2020

  Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, announced recent progress in its gene therapy programs, including a 12-month update on its Parkinson’s program.

• Axovant Provides Clinical Program Update for AXO-AAV-GM1, a Novel Investigational Gene Therapy for GM1 Gangliosidosis

  12/19/2019

  Axovant Gene Therapies Ltd. (NASDAQ: AXGT) today announced preliminary findings from an expanded access treatment in which a single patient with GM1 gangliosidosis was administered investigational AXO-AAV-GM1 gene therapy

• Axovant Announces Amendment to Credit Facility with Hercules Capital

  12/3/2019

  Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced the completion of an amendment to its loan and security agreement with Hercules Capital, Inc. (“Hercules”)

• Axovant Gene Therapies Receives Orphan Drug Designation from FDA for AXO-AAV-GM1 for the Treatment of GM1 Gangliosidosis

  11/18/2019

  Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company’s investigational gene therapy, AXO-AAV-GM1, for the treatment of GM1 gangliosidosis.